Literature DB >> 15489894

Distinct profiles of critically short telomeres are a key determinant of different chromosome aberrations in immortalized human cells: whole-genome evidence from multiple cell lines.

Wen Deng1, Sai Wah Tsao, Xin-Yuan Guan, Joe N Lucas, Hua Xin Si, Chi Shing Leung, Priscilla Mak, Li Dong Wang, Annie L M Cheung.   

Abstract

Chromosomal aberrations are common in cancers. However, the search for chromosomal aberrations leading to development of specific solid tumors has been severely hindered because the majority of solid tumors have complex chromosomal aberrations that differ within the same tumor types. A similar phenomenon exists in immortalized cell lines. The underlying mechanisms driving these diverse aberrations are largely unknown. Telomeres play crucial roles in protecting the integrity of eucaryotic chromosomes and maintaining genomic stability of human cells. Telomere lengths on individual chromosomes in normal human somatic cells are heterogeneous and undergo progressive shortening with aging process. In this study, for the first time, a molecular cytogenetic method using sequential telomere quantitative fluorescence in situ hybridization and spectral karyotyping on the same human metaphases was applied successfully to examine the dynamic profiles of individual telomere shortening and their relationship to chromosome aberrations in multiple human cell lines undergoing immortalization. Human ovarian surface epithelial cells and esophageal epithelial cells were immortalized by the expression of HPV16 E6 and E7, which drive cells to proliferate by inactivating p53 and Rb genes. In these cell lines, we consistently detected large-scale differences in telomere signal intensities not only among nonhomologous chromosome arms but also between some homologous chromosome arms. The cell lines derived from different donors had different profiles of critically short telomeres (lacking telomere signals). Strikingly, the different profiles of chromosomal structural aberrations in multiple immortalized cell lines were highly significantly associated with the distinct distributions of critically short telomeres in whole-genome. Since cellular immortalization is one of the hallmarks of cancer, our findings suggest that distinct profiles of critically short telomeres in different human individuals might play an essential role in determining the complex and individual-specific chromosomal structural aberrations in human solid tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15489894     DOI: 10.1038/sj.onc.1208119

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

1.  Microtubule breakage is not a major mechanism for resolving end-to-end chromosome fusions generated by telomere dysfunction during the early process of immortalization.

Authors:  W Deng; S W Tsao; X-Y Guan; A L M Cheung
Journal:  Chromosoma       Date:  2007-08-28       Impact factor: 4.316

2.  β-catenin downregulates Dicer to promote ovarian cancer metastasis.

Authors:  S K Y To; A S C Mak; Y M Eva Fung; C-M Che; S-S Li; W Deng; B Ru; J Zhang; A S T Wong
Journal:  Oncogene       Date:  2017-06-26       Impact factor: 9.867

3.  Identification of a novel tumor transforming gene GAEC1 at 7q22 which encodes a nuclear protein and is frequently amplified and overexpressed in esophageal squamous cell carcinoma.

Authors:  F B F Law; Y W Chen; K Y Wong; J Ying; Q Tao; C Langford; P Y Lee; S Law; R W L Cheung; C H Chui; S W Tsao; K Y Lam; J Wong; G Srivastava; J C O Tang
Journal:  Oncogene       Date:  2007-03-26       Impact factor: 9.867

4.  Oncogene GAEC1 regulates CAPN10 expression which predicts survival in esophageal squamous cell carcinoma.

Authors:  Dessy Chan; Miriam Yuen-Tung Tsoi; Christina Di Liu; Sau-Hing Chan; Simon Ying-Kit Law; Kwok-Wah Chan; Yuen-Piu Chan; Vinod Gopalan; Alfred King-Yin Lam; Johnny Cheuk-On Tang
Journal:  World J Gastroenterol       Date:  2013-05-14       Impact factor: 5.742

5.  Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas.

Authors:  H Jin; X Wang; J Ying; A H Y Wong; H Li; K Y Lee; G Srivastava; A T C Chan; W Yeo; B B Y Ma; T C Putti; M L Lung; Z-Y Shen; L-Y Xu; C Langford; Q Tao
Journal:  Oncogene       Date:  2007-06-04       Impact factor: 9.867

6.  SAA1 polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinoma.

Authors:  H L Lung; O Y Man; M C Yeung; J M Y Ko; A K L Cheung; E W L Law; Z Yu; W H Shuen; E Tung; S H K Chan; D K Bangarusamy; Y Cheng; X Yang; R Kan; Y Phoon; K C Chan; D Chua; D L Kwong; A W M Lee; M F Ji; M L Lung
Journal:  Oncogene       Date:  2014-03-10       Impact factor: 9.867

7.  Overexpression of eIF-5A2 in mice causes accelerated organismal aging by increasing chromosome instability.

Authors:  Muhan Chen; Jian-Dong Huang; Hong Kui Deng; Suisui Dong; Wen Deng; Sze Lan Tsang; Michael S Y Huen; Leilei Chen; Tong Zan; Gui-Xia Zhu; Xin-Yuan Guan
Journal:  BMC Cancer       Date:  2011-05-26       Impact factor: 4.430

8.  DNA-PKcs inhibition sensitizes cancer cells to carbon-ion irradiation via telomere capping disruption.

Authors:  Xin Zhou; Xin Zhang; Yi Xie; Kaoru Tanaka; Bing Wang; Hong Zhang
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

9.  Pericentromeric regions are refractory to prompt repair after replication stress-induced breakage in HPV16 E6E7-expressing epithelial cells.

Authors:  Wen Deng; Sai Wah Tsao; Xin-Yuan Guan; Annie L M Cheung
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

10.  OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation.

Authors:  Yan Cui; Ying Ying; Andrew van Hasselt; Ka Man Ng; Jun Yu; Qian Zhang; Jie Jin; Dingxie Liu; Johng S Rhim; Sun Young Rha; Myriam Loyo; Anthony T C Chan; Gopesh Srivastava; George S W Tsao; Grant C Sellar; Joseph J Y Sung; David Sidransky; Qian Tao
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.